Magle Chemoswed Holding Past Earnings Performance
Past criteria checks 5/6
Magle Chemoswed Holding has been growing earnings at an average annual rate of 30.7%, while the Life Sciences industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 10.2% per year. Magle Chemoswed Holding's return on equity is 7.6%, and it has net margins of 7.1%.
Key information
30.7%
Earnings growth rate
23.3%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 10.2% |
| Return on equity | 7.6% |
| Net Margin | 7.1% |
| Next Earnings Update | 18 Jul 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Magle Chemoswed Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 171 | 12 | 132 | 0 |
| 31 Dec 23 | 171 | 12 | 131 | 0 |
| 30 Sep 23 | 170 | 10 | 131 | 0 |
| 30 Jun 23 | 158 | 9 | 121 | 0 |
| 31 Mar 23 | 155 | 8 | 120 | 0 |
| 31 Dec 22 | 148 | 9 | 113 | 0 |
| 30 Sep 22 | 138 | 10 | 106 | 0 |
| 30 Jun 22 | 136 | 10 | 108 | 0 |
| 31 Mar 22 | 133 | 7 | 106 | 0 |
| 31 Dec 21 | 132 | 4 | 106 | 0 |
| 30 Sep 21 | 137 | 3 | 105 | 0 |
| 30 Jun 21 | 133 | 1 | 99 | 0 |
| 31 Mar 21 | 134 | 2 | 99 | 0 |
| 31 Dec 20 | 142 | 2 | 100 | 0 |
| 30 Sep 20 | 151 | 14 | 103 | 0 |
| 30 Jun 20 | 140 | 8 | 104 | 0 |
| 31 Mar 20 | 137 | 1 | 100 | 0 |
| 31 Dec 19 | 132 | 1 | 96 | 0 |
| 31 Dec 18 | 110 | -3 | 99 | 0 |
Quality Earnings: 52X has high quality earnings.
Growing Profit Margin: 52X's current net profit margins (7.1%) are higher than last year (5.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 52X has become profitable over the past 5 years, growing earnings by 30.7% per year.
Accelerating Growth: 52X's earnings growth over the past year (53.8%) exceeds its 5-year average (30.7% per year).
Earnings vs Industry: 52X earnings growth over the past year (53.8%) exceeded the Life Sciences industry 6.5%.
Return on Equity
High ROE: 52X's Return on Equity (7.6%) is considered low.